These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 26953284)

  • 1. Comparative resource utilization and costs for patients with acute coronary syndrome managed with percutaneous coronary intervention and treated with clopidogrel or prasugrel.
    Bae JP; Faries DE; Ernst FR; Lipkin C; Zhao Z; Moretz C; Lieu HD; Effron MB
    Am J Health Syst Pharm; 2016 Mar; 73(6):395-403. PubMed ID: 26953284
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of healthcare resource utilization and costs in patients hospitalized for acute coronary syndrome managed with percutaneous coronary intervention and receiving prasugrel or ticagrelor.
    Molife C; Frech-Tamas F; DeKoven M; Effron MB; Karkare S; Zhu Y; Larmore C; Lu J; McCollam P; Marrett E; Vetrovec GW
    J Med Econ; 2015; 18(11):898-908. PubMed ID: 26086414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic outcomes with prasugrel versus clopidogrel in acute coronary syndrome patients: observations from prasugrel users and matched clopidogrel users.
    Olson WH; Ma YW; Crivera C; Schein J; Lefebvre P; Laliberté F; Dea K; Germain G; Lynch SM
    J Med Econ; 2015; 18(12):1074-84. PubMed ID: 26407193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 6-Month Costs Between Oral Antiplatelet Agents Following Acute Coronary Syndrome.
    Kim K; Lee TA; Touchette DR; DiDomenico RJ; Ardati AK; Walton SM
    J Manag Care Spec Pharm; 2018 Aug; 24(8):800-812. PubMed ID: 30058986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
    Bae JP; Faries DE; Ernst FR; Lipkin C; Zhao Z; Moretz C; Lieu HD; Effron MB
    Curr Med Res Opin; 2014 Nov; 30(11):2207-16. PubMed ID: 25034466
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prasugrel compared to clopidogrel in patients with acute coronary syndrome undergoing percutenaous coronary intervention: a Spanish model-based cost effectiveness analysis.
    Davies A; Sculpher M; Barrett A; Huete T; Sacristán JA; Dilla T
    Farm Hosp; 2013; 37(4):307-16. PubMed ID: 24010692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP2C19 LOF and GOF-Guided Antiplatelet Therapy in Patients with Acute Coronary Syndrome: A Cost-Effectiveness Analysis.
    Jiang M; You JH
    Cardiovasc Drugs Ther; 2017 Feb; 31(1):39-49. PubMed ID: 27924429
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.
    Kurz DJ; Radovanovic D; Seifert B; Bernheim AM; Roffi M; Pedrazzini G; Windecker S; Erne P; Eberli FR
    Eur Heart J Acute Cardiovasc Care; 2016 Feb; 5(1):13-22. PubMed ID: 25614494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns and outcomes in patients undergoing percutaneous coronary intervention treated with prasugrel or clopidogrel (from the Swedish Coronary Angiography and Angioplasty Registry [SCAAR]).
    Damman P; Varenhorst C; Koul S; Eriksson P; Erlinge D; Lagerqvist B; James SK
    Am J Cardiol; 2014 Jan; 113(1):64-9. PubMed ID: 24169009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Proton Pump Inhibitor Use on the Comparative Effectiveness and Safety of Prasugrel Versus Clopidogrel: Insights From the Treatment With Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events After Acute Coronary Syndrome (TRANSLATE-ACS) Study.
    Jackson LR; Peterson ED; McCoy LA; Ju C; Zettler M; Baker BA; Messenger JC; Faries DE; Effron MB; Cohen DJ; Wang TY
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.
    Larmore C; Effron MB; Molife C; DeKoven M; Zhu Y; Lu J; Karkare S; Lieu HD; Lee WC; Vetrovec GW
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):535-544. PubMed ID: 26577386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.
    Akita K; Inohara T; Yamaji K; Kohsaka S; Numasawa Y; Ishii H; Amano T; Kadota K; Nakamura M; Maekawa Y
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):231-238. PubMed ID: 31593213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and planned percutaneous coronary intervention: results from the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial Infarction TRITON-TIMI 38.
    Mahoney EM; Wang K; Arnold SV; Proskorovsky I; Wiviott S; Antman E; Braunwald E; Cohen DJ
    Circulation; 2010 Jan; 121(1):71-9. PubMed ID: 20026770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk.
    Baber U; Leisman DE; Cohen DJ; Gibson CM; Henry TD; Dangas G; Moliterno D; Kini A; Krucoff M; Colombo A; Chieffo A; Sartori S; Witzenbichler B; Steg PG; Pocock SJ; Mehran R
    Circ Cardiovasc Qual Outcomes; 2019 Jan; 12(1):e004945. PubMed ID: 30606052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guided de-escalation of antiplatelet treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention (TROPICAL-ACS): a randomised, open-label, multicentre trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Holdt L; Felix SB; Parma R; Klopotowski M; Schwinger RHG; Rieber J; Huber K; Neumann FJ; Koltowski L; Mehilli J; Huczek Z; Massberg S;
    Lancet; 2017 Oct; 390(10104):1747-1757. PubMed ID: 28855078
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prasugrel vs. clopidogrel in contemporary Western European patients with acute coronary syndromes receiving drug-eluting stents: Comparative cost-effectiveness analysis from the BASKET-PROVE cohorts.
    Wein B; Coslovsky M; Jabbari R; Galatius S; Pfisterer M; Kaiser C
    Int J Cardiol; 2017 Dec; 248():20-27. PubMed ID: 28823409
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Prasugrel Compared With Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention.
    Wang A; Lella LK; Brener SJ
    Am J Ther; 2016; 23(6):e1637-e1643. PubMed ID: 24942006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clopidogrel, prasugrel or ticagrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention.
    Yudi MB; Clark DJ; Farouque O; Eccleston D; Andrianopoulos N; Duffy SJ; Brennan A; Lefkovits J; Ramchand J; Yip T; Oqueli E; Reid CM; Ajani AE;
    Intern Med J; 2016 May; 46(5):559-65. PubMed ID: 26909472
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.